Nanjing Medlander Medical Technology Co. Ltd. Class A
SSSE:68827326.32
CNY
-0.29
(-1.09%)
ISIN
CNE100005PV8
Return %
Stock
S&P 500
1Y
-32.77
14.20
3Y
-14.55
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Rui Jia Yang
- Full Time Employees
- 550
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Nanjing China
- IPO Date
- Aug 11, 2022
- Website
- medlander.com
- Similar Companies
- Business
- Nanjing Medlander Medical Technology Co., Ltd. develops, manufactures, and commercializes medical devices, clinical consumables, and healthcare software solutions focused on pelvic floor health, obstetrics and gynecology rehabilitation, reproductive medicine, medical aesthetics, and neuromodulation. The company operates through several specialized product and service segments, including Pelvic Floor and Postpartum Rehabilitation Equipment, comprising biological feedback and electrical stimulation devices under the MLD B and MLD M series, high-intensity pulsed magnetic stimulation systems, pelvic surface electromyography analysis systems, and the PI-ONE intelligent pelvic diagnosis and treatment platform; Reproductive Rehabilitation and Anti-Aging Systems, featuring electro-ultrasound therapy systems and multimodal acoustic, optical, electrical, thermal, and magnetic therapeutic devices marketed under brand lines such as Weizhilan; Medical Consumables and Accessories, providing specialized vaginal electrodes, rectal electrodes, and clinical probes designed for pelvic assessment and treatment; Movement and Motor Rehabilitation Systems, including hand-function magnetic stimulation devices and joint rehabilitation assessment tools; Medical Aesthetic and Dermatological Devices, consisting of AI-powered skin analysis systems, therapeutic ultrasound systems for facial wrinkle reduction, and Nd:YAG picosecond laser treatment platforms; and Clinical Informatics Solutions, delivering cloud-based pelvic healthcare management software and hospital-grade tiered diagnosis and treatment platforms. The company serves public and private general hospitals, maternal and child healthcare institutions, obstetrics and gynecology departments, pelvic rehabilitation centers, urology and anorectal clinics, reproductive medicine centers, postpartum recovery institutions, and medical aesthetic clinics primarily throughout China as well as international markets across Asia and the Middle East. Founded in 2013 and headquartered in Nanjing, China, the company trades on the Shanghai Stock Exchange STAR Market under ticker 688273. In recent corporate developments, Nanjing Medlander Medical Technology Co., Ltd. has executed a strategic transition toward a dual-engine growth model integrating clinical medical equipment with consumer healthcare and neuro-rehabilitation technologies. Recent operational highlights include entering into a strategic partnership with Beauty Farm to advance gynecological anti-aging research and clinical applications; establishing strategic research and clinical collaboration with Hangzhou Rongnao Technology Co., Ltd. alongside a strategic equity investment to co-develop brain-computer interface and neural modulation technologies; securing Class II medical device regulatory approvals for its proprietary ultrasound therapy system for facial skin firming and its Nd:YAG picosecond laser therapy system; and integrating generative AI algorithms into its dermatological diagnostic tools and digital pelvic diagnosis workflows.